Various clinical data demonstrate the crucial role CGRP plays in migraine pathology, and there are several different methods of blocking CGRP activity to treat migraine attacks.
1. Gepants – CGRP receptor antagonists, which bind to the CGRP receptor and prevent signalling.
2. Anti-CGRP antibodies, which prevent CGRP interacting with its receptor.
3. Anti-CGRP receptor antibodies, which bind to the CGRP receptor and prevent signalling.
Read more about anti-CGRP therapies and their mechanism of action
Related content
Discover how human models of migraine have identified key molecular triggers like CGRP and PACAP, revolutionizing treatment options and offering hope for patients unresponsive to current therapies.
Migraine is a prevalent neurological disorder characterized by recurrent and disabling attacks of moderate to severe headache
Migraine affects an estimated 1.1 billions worldwide and ranks as the 2nd leading cause of disability, while being the leading among young adults.